In a first-in-human phase 1/2 trial examining enasidenib (AG-221/CC-90007) in IDH2-mutated relapsed or refractory AML, the ORR was 40.3% and the median OS was 9.3 months [85]. The gene discussed is IDH2; the disease is acute myeloid leukemia.